Action Exagen - XGN

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

5,02

Prix Achat

4,65

Prix Vente

5,60

Volume échangé

65 825

4,68 Fourchette du Jour 5,30

1,3003 Plage de 52 semaines 6,21

Cap du marché

88,539M

Clôture Veille

4,95

Ouverture

5,10

Dernière Transaction

180

5.28

(formt)

Dernière heure de transaction

Volume financier

US$ 329 295

VWAP

5,0026

Volume moyen (3 m)

82 609

Actions en circulation

17 637 278

Rendement du Dividende

Ratio Cours sur Bénéfices

-3,74

Bénéfice par action (BPA)

-1,34

Chiffre d'affairess

52,55M

Bénéfice net

-23,69M

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differentia... Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. Show more

Secteur

Medical Laboratories

Industrie

Medical Laboratories

Site Web

www.exagen.com

Siège social

Wilmington, Delaware, USA

Fondé

Exagen Inc est coté dans le secteur Medical Laboratories de la NASDAQ avec le ticker XGN. Le dernier cours de clôture d'Exagen était de US$4,95. Au cours de la dernière année, les actions de Exagen ont été négociées dans une fourchette de prix de US$ 1,3003 à US$ 6,21.

Exagen compte actuellement 17 637 278 actions en circulation. La capitalisation boursière d'Exagen est de US$87,30 million. Exagen a un ratio cours/bénéfice (ratio PE) de -3.74.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...

Form 4 - Statement of changes in beneficial ownership of securities

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-1.05	-17.2981878089	6.07	6.12	4.71	145565	5.30257259	CS
4	0.8214	19.5636640785	4.1986	6.21	3.7201	156616	5.2665095	CS
12	2.05	69.0235690236	2.97	6.21	2.38	82609	4.6157537	CS
26	3.08	158.762886598	1.94	6.21	1.71	66161	3.83784625	CS
52	3.3	191.860465116	1.72	6.21	1.3003	55391	3.06233064	CS
156	-5.92	-54.113345521	10.94	11.68	1.3003	44566	3.74673513	CS
260	-21.98	-81.4074074074	27	29.858	1.3003	46302	8.85105085	CS

XGN - Frequently Asked Questions (FAQ)

What is the current Exagen share price?

The current share price of Exagen is US$ 5,02

How many Exagen shares are in issue?

Exagen has 17 637 278 shares in issue

What is the market cap of Exagen?

The market capitalisation of Exagen is USD 87,3M

What is the 1 year trading range for Exagen share price?

Exagen has traded in the range of US$ 1,3003 to US$ 6,21 during the past year

What is the PE ratio of Exagen?

The price to earnings ratio of Exagen is -3,74

What is the cash to sales ratio of Exagen?

The cash to sales ratio of Exagen is 1,68

What is the reporting currency for Exagen?

Exagen reports financial results in USD

What is the latest annual turnover for Exagen?

The latest annual turnover of Exagen is USD 52,55M

What is the latest annual profit for Exagen?

The latest annual profit of Exagen is USD -23,69M

What is the registered address of Exagen?

The registered address for Exagen is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Exagen website address?

The website address for Exagen is www.exagen.com

Which industry sector does Exagen operate in?

Exagen operates in the MEDICAL LABORATORIES sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
BAOSBaosheng Media Group Holdings Ltd	US$ 7,10 (310,40%)	58,74M
HOURHour Loop Inc	US$ 4,40 (207,69%)	97,42M
GTIGraphjet Technology	US$ 0,61 (168,72%)	265,48M
CREVCarbon Revolution Public Ltd	US$ 9,16 (135,48%)	26,95M
AVGRAvinger Inc	US$ 1,45 (125,72%)	107,53M
SLGLSol Gel Technologies Ltd	US$ 0,9798 (-40,62%)	3,07M
DRCTDirect Digital Holdings Inc	US$ 3,71 (-32,55%)	23,82M
CHEKCheck Cap Ltd	US$ 1,55 (-31,11%)	3,49M
SYTASiyata Mobile Inc	US$ 0,5178 (-30,83%)	2,63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF	US$ 15,47 (-30,38%)	147,98k
SVMHSRIVARU Holding Ltd	US$ 0,0338 (20,71%)	280,27M
GTIGraphjet Technology	US$ 0,61 (168,72%)	265,48M
LITMSnow Lake Resources Ltd	US$ 0,5849 (52,84%)	181,22M
LCIDLucid Group Inc	US$ 3,20 (3,23%)	108,75M
RGTIRigetti Computing Inc	US$ 11,35 (3,56%)	108,38M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Exagen Inc (XGN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Exagen Inc

XGN Dernières nouvelles

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. Reports Third Quarter 2024 Results

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. Reports Third Quarter 2024 Results

XGN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Exagen Inc (XGN) Cours

Exagen Inc (XGN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Exagen Inc

XGN Dernières nouvelles

XGN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application